Navigation Links
ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Date:4/1/2008

we will have further encouraging results from this trial."

About Vitrectomy

Approximately 600,000 surgical vitrectomies are performed annually worldwide. The U.S. market accounts for more than 40% of treatments, and is growing at 6-8% per year. During a vitrectomy, three incisions are made through the white of the eye; the surgeon then inserts small instruments into the eye, cuts the vitreous gel, and suctions it out. There are certain risks inherent to this surgery including bleeding, infection, increased eye pressure, retinal detachment, and development of cataracts.

As Microplasmin could induce a PVD without the need for vitrectomy, it may serve as a more convenient, less invasive treatment option for certain eye conditions. For example, results from ThromboGenics' MIVI II Traction trial, which examined the safety and efficacy of Microplasmin in the treatment of vitreomacular traction showed that Microplasmin was able to resolve vitreomacular traction and even achieve closure of some macular holes, conditions that otherwise would have required vitrectomy.

Other major eye diseases that may benefit from nonsurgical PVD induction include diabetic retinopathy and age-related macular degeneration (AMD). Diabetic retinopathy is the leading cause of blindness among working-age adults, while AMD is the leading cause of blindness among the elderly.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clini
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
2. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
6. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
7. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
8. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
9. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
10. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
11. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... Inc. (Nasdaq: STXS ) today announced that executive ... Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. A live audio and slides webcast of Stereotaxis, ...
... BEDFORD, Mass., Sept. 23 Instrumentation Laboratory (IL), today announced ... on Wednesday, October 13, 2010 at the Grand Hyatt Nusa ... am to 12:00 pm, local time.  The forum will focus ... hemostasis.  All healthcare professionals, practicing in the Asia Pacific region ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
(Date:12/19/2014)... December 19, 2014 Energy Textiles ... are now available. Celliant, the world’s leading responsive ... and pillowcases. , There are a number of ... circulation, increased oxygenation and balanced body temperature; which ... and pain relief; enhanced athletic performance; and overall ...
(Date:12/19/2014)... 2014 SuperCloset raises the bar once ... continues to offer indoor growers the most efficient and ... new SuperClone Rooms with the award winning SuperRooms ... hydroponic grow room setup. , The SuperClone Room features ... SuperCloner 50 . The SuperClone Room ...
(Date:12/19/2014)... 20, 2014 An evening dress is perfect ... lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its ... dresses in this great shopping platform. Customers can ... staff's hard work, Discount-Dress.com has been accepted and praised by ... and easier shopping stage for clients. In order to expand ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... who are diagnosed with bone cancer could benefit from better ... University of Nottingham. The Bone Cancer Research Trust launches ... project at the University which is testing a theory that ... Researchers at the School of Clinical Sciences, Division of ...
... Reporter , MONDAY, Oct. 11 (HealthDay News) -- The ... involving human embryonic stem cells has been injected with ... patient, being cared for at the Shepherd Center in ... The center specializes in treating these types of injuries. ...
... last six months of life has become progressively more expensive ... the United States and older adults in Canada, with a ... life in both countries, according to two reports posted online ... issue of Archives of Internal Medicine , one of ...
... intravitreous (into the eye) injection of a chemotherapy drug ... against the eye diseasedo not appear to be associated ... when compared with existing therapies, according to a report ... , one of the JAMA/Archives journals. "More than ...
... Oct. 11 (HealthDay News) -- Women with epilepsy may be at ... The study included 375 women who planned to have a ... or for up to 10 years. During the study period, 62 ... among women with epilepsy was more than twice the 15 percent ...
... of a computer or television screen are more likely to ... The PEACH project, a study of over a 1,000 ... spent in front of a screen as well as their ... children,s sedentary time and moderate physical activity. The results ...
Cached Medicine News:Health News:Hope for a new treatment for bone cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Study Sees Link Between Epilepsy, Infertility 2Health News:Screen time linked to psychological problems in children 2
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances....
... With the Hertel, the unit ... and held firmly against the ... with the center of the ... the two temporal orbital walls, ...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
Medicine Products: